Novo Nordisk, AWS partner on AI drug discovery
The basics: Novo Nordisk names AWS as strategic AI partner Collaboration aims to accelerate drug discovery New London…
Novo Nordisk’s Wegovy: Pioneering Weight Loss Innovation
Novo Nordisk, the Danish pharmaceutical giant, is intensifying its pursuit of weight-loss innovation with a new late-stage study…
Novo Nordisk’s Strategic Move with Wegovy: A New Study in the Obesity Drug Race
Novo Nordisk, a leading Danish pharmaceutical company, has embarked on a late-stage study to identify the minimal effective…
Novo Nordisk CEO defends lawsuit against Eli Lilly: ‘Competition has to be fair’
Novo Nordisk CEO Mike Doustdar on Wednesday defended the drugmaker’s decision to sue rival Eli Lilly over its…
Foundayo: Eli Lilly wins U.K. approval, challenging Wegovy weight-loss pill
Eli Lilly has won its first approval to sell its weight-loss drug Foundayo outside the U.S., allowing it…
Novo Nordisk updates 2026 share buyback totals | NVO SEC Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF…
Eli Lilly, Novo Nordisk earnings show widening divide in GLP-1 market
The Eli Lilly and Novo Nordisk logos. Mike Blake | Tom Little | Reuters The diverging paths of…
Novo defends economics of Wegovy pill as lower prices weigh on sales; stock falls
Novo Nordisk‘s CEO sought to reassure investors that its Wegovy pill can drive profitable growth despite lower prices,…
Novo CEO faces investor grilling after obesity drug disappointments
Ozempic manufacturer Novo Nordisk faces challenges as the patent on semaglutide expire in one country after the other.…
Novo Nordisk stock falls as raised outlook fails to change the debate over obesity business
Novo Nordisk’s quarterly beat and guidance increase did little to resolve Wall Street’s biggest concern: whether the Ozempic…
Obesity battle heats up again as Novo claws its way back into race with Lilly
London – Novo Nordisk investors have found little cause for optimism during a bruising two-year period of profit…
Novo Nordisk shares fall after heart medicine trial results
Shares of Novo Nordisk fell as much as 10% on Friday after the drugmaker said a late-stage heart…